U.s. veterinary oncologists participating in a new survey prefer canalevia-ca1 over the current standard of care

91.67% of respondents to a question asking how they see themselves using the product in the future indicated they plan on increasing use of canalevia®-ca1 over time canalevia-ca1, jaguar health's fda conditionally approved drug for chemotherapy-induced diarrhea (cid) in dogs, is the first and only treatment for cid in dogs to receive any type of approval from the fda san francisco, ca / accesswire / april 27, 2023 / jaguar health, inc. (nasdaq:jagx) ("jaguar") today announced the results of a survey of 26 u.s. veterinary oncologists regarding canalevia-ca1, the company's u.s. food and drug administration (fda) conditionally approved prescription drug product for the treatment of chemotherapy-induced diarrhea (cid) in dogs. the study was conducted by jaguar at the veterinary cancer society (vcs) collaborative conference, which took place april 19-22, 2023 in cancun, mexico.
JAGX Ratings Summary
JAGX Quant Ranking